Dutta P, Sett A, Sarkar A, Mitra U, Saha D, Manna B, Kundu B, Gupta A
Division of Clinical Medicine, National Institute of Cholera and Enteric Diseases, Beliaghata, Calcutta.
Indian Pediatr. 1995 Jan;32(1):13-9.
Efficacy of furazolidone and nalidixic acid was compared in a randomized trial involving 72 children with acute invasive diarrhea. Thirty six children received furazolidone (7.5 mg/kg/day) and 36 children received nalidixic acid (55 mg/kg/day). Clinical characteristics of the two treatment groups were comparable on admission. Of these, 34 children in furazolidone treated group and 29 children in nalidixic acid treated group completed the full course of treatment and were analyzed finally for clinical efficacy. Clinical cure was observed in 29(85.3%) children treated with furazolidone and 29(100.0%) children treated with nalidixic acid. Nalidixic acid treated group had statistically significantly higher cure rate (p = 0.039) as compared to furazolidone treated group. However, 85% cure rate in furazolidone treated group may be potentially useful for the treatment of acute invasive diarrhea because of decreasing efficacy of nalidixic acid against shigellosis in many countries.
在一项涉及72名急性侵袭性腹泻儿童的随机试验中，比较了呋喃唑酮和萘啶酸的疗效。36名儿童接受呋喃唑酮治疗（7.5毫克/千克/天），36名儿童接受萘啶酸治疗（55毫克/千克/天）。两个治疗组的临床特征在入院时具有可比性。其中，呋喃唑酮治疗组的34名儿童和萘啶酸治疗组的29名儿童完成了整个疗程，并最终对临床疗效进行了分析。接受呋喃唑酮治疗的29名（85.3%）儿童和接受萘啶酸治疗的29名（100.0%）儿童观察到临床治愈。与呋喃唑酮治疗组相比，萘啶酸治疗组的治愈率在统计学上显著更高（p = 0.039）。然而，由于在许多国家萘啶酸对志贺菌病的疗效下降，呋喃唑酮治疗组85%的治愈率可能对急性侵袭性腹泻的治疗有潜在作用。
